ISCT leader Bill Milligan, Chair of the Business Models and Cost of Goods Subcommittee speaks on behalf of ISCT to the Wall Street Journal.
August 28 - The Promising New Cancer Treatment Behind Gilead's $11 Billion Deal. Read the Article »
#PressReleases